Clinically used drug arsenic trioxide targets XIAP and overcomes apoptosis resistance in an organoid-based preclinical cancer model-Reference-Cited by-同舟云学术

Clinically used drug arsenic trioxide targets XIAP and overcomes apoptosis resistance in an organoid-based preclinical cancer model

Published:2024 Issue:22 Volume:15 Page:8311-8322
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Shi Liwa¹²,Lu Jing¹²³,Xia Xin¹²,Liu Xue¹²,Li Hongyan⁴,Li Xinghua⁵,Zhu Jun¹²^ORCID,Li Xiaofeng³,Sun Hongzhe⁴^ORCID,Yang Xinming¹²^ORCID

Affiliation:

1. Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China

2. Guangdong-Hong Kong-Macao University Joint Laboratory of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, China

3. Department of Gastroenterology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China

4. Department of Chemistry, CAS-HKU Joint Laboratory of Metallomics on Health and Environment, The University of Hong Kong, Hong Kong SAR, China

5. Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China

Abstract

Drug resistance in tumor cells remains a persistent clinical challenge in the pursuit of effective anticancer therapy. Herein, we repurpose clinically used drug arsenic trioxide to target XIAP and overcome cisplatin drug resistance in tumors.

Funder

Research Grants Council, University Grants Committee

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/SC/D4SC01294A

Reference58 articles.

1. Targeting IAP proteins for therapeutic intervention in cancer

2. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family

3. Targeting XIAP for the treatment of malignancy

4. Caspases in Cell Death, Inflammation, and Pyroptosis

5. A novel role for XIAP in copper homeostasis through regulation of MURR1